ACIU Pfcf Ratio from 2010 to 2024

ACIU Stock  USD 3.38  0.09  2.74%   
AC Immune PFCF Ratio yearly trend continues to be comparatively stable with very little volatility. PFCF Ratio will likely drop to -6.11 in 2024. From the period from 2010 to 2024, AC Immune PFCF Ratio quarterly data regression had mean square error of  747.43 and mean deviation of  20.49. View All Fundamentals
 
PFCF Ratio  
First Reported
2010-12-31
Previous Quarter
(5.82)
Current Value
(6.11)
Quarterly Volatility
28.70271183
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AC Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AC Immune's main balance sheet or income statement drivers, such as Interest Expense of 167.2 K, Selling General Administrative of 8.3 M or Total Revenue of 20 M, as well as many indicators such as Price To Sales Ratio of 38.71, Dividend Yield of 0.0 or PTB Ratio of 2.11. ACIU financial statements analysis is a perfect complement when working with AC Immune Valuation or Volatility modules.
  
Check out the analysis of AC Immune Correlation against competitors.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

Latest AC Immune's Pfcf Ratio Growth Pattern

Below is the plot of the Pfcf Ratio of AC Immune over the last few years. It is AC Immune's PFCF Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AC Immune's overall financial position and show how it may be relating to other accounts over time.
Pfcf Ratio10 Years Trend
Slightly volatile
   Pfcf Ratio   
       Timeline  

ACIU Pfcf Ratio Regression Statistics

Arithmetic Mean(19.99)
Coefficient Of Variation(143.61)
Mean Deviation20.49
Median(12.52)
Standard Deviation28.70
Sample Variance823.85
Range121
R-Value0.40
Mean Square Error747.43
R-Squared0.16
Significance0.14
Slope2.55
Total Sum of Squares11,534

ACIU Pfcf Ratio History

2024 -6.11
2023 -5.82
2022 -2.11
2021 -4.95
2020 -5.38
2019 10.91
2018 -12.52

About AC Immune Financial Statements

AC Immune shareholders use historical fundamental indicators, such as Pfcf Ratio, to determine how well the company is positioned to perform in the future. Although AC Immune investors may analyze each financial statement separately, they are all interrelated. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses on on AC Immune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
PFCF Ratio(5.82)(6.11)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.